Drug discovery requires two separate steps: checking whether a drug can bind to a harmful molecule or its receptor, and ...

A new editorial paper was published in Oncoscience, titled "PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors; PARs." While targeted cancer therapy is greatly ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

In this study in silico docking models were employed to investigate the molecular interactions between the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein, derived from the ...

New study shows how bacteria adapted a virus-derived injection system to recognize and attach to many different types of ...

A bitter taste receptor, TAS2R14, has been shown to respond to both extracellular and intracellular signals. Indeed, it can respond to both signals simultaneously. This finding is especially ...

Scientists have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is ...

HOUSTON, Feb. 3, 2026 /PRNewswire/ -- Deep EigenMatics, Inc., a pioneer in high-velocity Artificial Intelligence for drug design, announced today that it has secured the #1 global ranking for new U.S.

Habegger is a professor in the UAB Department of Medicine Division of Endocrinology, Diabetes and Metabolism and also a scientist in the UAB Nutrition Obesity Research Center who studies how glucagon ...